Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase.
Charlotte A SoftleyKrzysztof M ZakMark J BostockRoberto FinoRichard Xu ZhouMarta KolonkoRamona Mejdi-NitiuHannelore MeyerMichael SattlerGrzegorz M PopowiczPublished in: Antimicrobial agents and chemotherapy (2020)
Multidrug resistance among Gram-negative bacteria is a major global public health threat. Metallo-β-lactamases (MBLs) target the most widely used antibiotic class, the β-lactams, including the most recent generation of carbapenems. Interspecies spread renders these enzymes a serious clinical threat, and there are no clinically available inhibitors. We present the crystal structures of IMP-13, a structurally uncharacterized MBL from the Gram-negative bacterium Pseudomonas aeruginosa found in clinical outbreaks globally, and characterize the binding using solution nuclear magnetic resonance spectroscopy and molecular dynamics simulations. The crystal structures of apo IMP-13 and IMP-13 bound to four clinically relevant carbapenem antibiotics (doripenem, ertapenem, imipenem, and meropenem) are presented. Active-site plasticity and the active-site loop, where a tryptophan residue stabilizes the antibiotic core scaffold, are essential to the substrate-binding mechanism. The conserved carbapenem scaffold plays the most significant role in IMP-13 binding, explaining the broad substrate specificity. The observed plasticity and substrate-locking mechanism provide opportunities for rational drug design of novel metallo-β-lactamase inhibitors, essential in the fight against antibiotic resistance.
Keyphrases
- gram negative
- multidrug resistant
- molecular dynamics simulations
- public health
- acinetobacter baumannii
- pseudomonas aeruginosa
- drug resistant
- transcription factor
- structural basis
- dna binding
- cystic fibrosis
- binding protein
- tissue engineering
- escherichia coli
- emergency department
- biofilm formation
- electronic health record